The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice

A common therapeutic strategy to combat human cancer is the use of combinations of drugs, each targeting different cellular processes or vulnerabilities. Recent studies suggest that addition of an MCL-1 inhibitor to such anticancer drug treatments could be an attractive therapeutic strategy. Thus, i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Differ
Asıl Yazarlar: Brinkmann, Kerstin, Grabow, Stephanie, Hyland, Craig D, Teh, Charis E, Alexander, Warren S, Herold, Marco J, Strasser, Andreas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Original Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686343/
https://ncbi.nlm.nih.gov/pubmed/28800129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2017.125
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller